Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies.

Tzarum N, Giang E, Kong L, He L, Prentoe J, Augestad E, Hua Y, Castillo S, Lauer GM, Bukh J, Zhu J, Wilson IA, Law M.

Sci Adv. 2019 Jan 2;5(1):eaav1882. doi: 10.1126/sciadv.aav1882. eCollection 2019 Jan.

2.

Probing the Antigenicity of HCV Envelope Glycoproteins by Phage Display Antibody Technology.

Giang E, Aleman F, Law M.

Methods Mol Biol. 2019;1911:381-393. doi: 10.1007/978-1-4939-8976-8_26.

PMID:
30593640
3.

Simultaneous Quantification of Hepatitis C Virus Envelope Glycoproteins E1 and E2 by Dual-Color Fluorescence Immunoblot Analysis.

Chen F, Giang E, Gopal R, Law M.

Methods Mol Biol. 2019;1911:295-304. doi: 10.1007/978-1-4939-8976-8_20.

PMID:
30593634
4.

Targeting discriminatory SNPs in Salmonella enterica serovar Heidelberg genomes using RNase H2-dependent PCR.

Labbé G, Rankin MA, Robertson J, Moffat J, Giang E, Lee LK, Ziebell K, MacKinnon J, Laing CR, Parmley EJ, Agunos A, Daignault D, Bekal S, Chui L, MacDonald KA, Hoang L, Slavic D, Ramsay D, Pollari F, Nash JHE, Johnson RP.

J Microbiol Methods. 2019 Feb;157:81-87. doi: 10.1016/j.mimet.2018.12.021. Epub 2018 Dec 25.

5.

Interrogation of Antigen Display on Individual Vaccine Nanoparticles for Achieving Neutralizing Antibody Responses against Hepatitis C Virus.

Bazzill JD, Ochyl LJ, Giang E, Castillo S, Law M, Moon JJ.

Nano Lett. 2018 Dec 12;18(12):7832-7838. doi: 10.1021/acs.nanolett.8b03601. Epub 2018 Nov 21.

PMID:
30461280
6.

Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.

Gopal R, Jackson K, Tzarum N, Kong L, Ettenger A, Guest J, Pfaff JM, Barnes T, Honda A, Giang E, Davidson E, Wilson IA, Doranz BJ, Law M.

PLoS Pathog. 2017 Dec 18;13(12):e1006735. doi: 10.1371/journal.ppat.1006735. eCollection 2017 Dec.

7.

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.

Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ, Tang J, Sok D, Burton DR, Law M, Ward AB, He L, Zhu J.

MBio. 2017 Feb 28;8(1). pii: e00036-17. doi: 10.1128/mBio.00036-17.

8.

Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.

Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, Garces F, Tzarum N, Woods VL Jr, Ward AB, Li S, Wilson IA, Law M.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12768-12773. doi: 10.1073/pnas.1609780113. Epub 2016 Oct 24.

9.

Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding.

He L, Cheng Y, Kong L, Azadnia P, Giang E, Kim J, Wood MR, Wilson IA, Law M, Zhu J.

Sci Rep. 2015 Aug 4;5:12501. doi: 10.1038/srep12501.

10.

Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.

Kong L, Kadam RU, Giang E, Ruwona TB, Nieusma T, Culhane JC, Stanfield RL, Dawson PE, Wilson IA, Law M.

J Mol Biol. 2015 Aug 14;427(16):2617-28. doi: 10.1016/j.jmb.2015.06.012. Epub 2015 Jun 30.

11.

Flexor tendon injury, repair and rehabilitation.

Lutsky KF, Giang EL, Matzon JL.

Orthop Clin North Am. 2015 Jan;46(1):67-76. doi: 10.1016/j.ocl.2014.09.004. Epub 2014 Oct 18. Review.

PMID:
25435036
12.

Broadly neutralizing antibodies abrogate established hepatitis C virus infection.

de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, Winer BY, Gerges S, Vega K, Labitt RN, Donovan BM, Giang E, Krishnan A, Chiriboga L, Charlton MR, Burton DR, Baltimore D, Law M, Rice CM, Ploss A.

Sci Transl Med. 2014 Sep 17;6(254):254ra129. doi: 10.1126/scitranslmed.3009512.

13.

Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.

Carlsen TH, Pedersen J, Prentoe JC, Giang E, Keck ZY, Mikkelsen LS, Law M, Foung SK, Bukh J.

Hepatology. 2014 Nov;60(5):1551-62. doi: 10.1002/hep.27298. Epub 2014 Oct 2.

14.

Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.

Ruwona TB, Giang E, Nieusma T, Law M.

J Virol. 2014 Sep;88(18):10459-71. doi: 10.1128/JVI.01584-14. Epub 2014 Jun 25. Erratum in: J Virol. 2014 Nov;88(22):13517.

15.

Post sex affectionate exchanges promote sexual and relationship satisfaction.

Muise A, Giang E, Impett EA.

Arch Sex Behav. 2014 Oct;43(7):1391-402. doi: 10.1007/s10508-014-0305-3. Epub 2014 Apr 29.

PMID:
24777441
16.

Hepatitis C virus E2 envelope glycoprotein core structure.

Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfield RL, Burton DR, Ward AB, Wilson IA, Law M.

Science. 2013 Nov 29;342(6162):1090-4. doi: 10.1126/science.1243876.

17.

Hepatitis B virus HBx protein impairs liver regeneration through enhanced expression of IL-6 in transgenic mice.

Quétier I, Brezillon N, Duriez M, Massinet H, Giang E, Ahodantin J, Lamant C, Brunelle MN, Soussan P, Kremsdorf D.

J Hepatol. 2013 Aug;59(2):285-91. doi: 10.1016/j.jhep.2013.03.021. Epub 2013 Mar 28.

PMID:
23542345
18.

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

Potiron VA, Abderrahmani R, Giang E, Chiavassa S, Di Tomaso E, Maira SM, Paris F, Supiot S.

Radiother Oncol. 2013 Jan;106(1):138-46. doi: 10.1016/j.radonc.2012.11.014. Epub 2013 Jan 12. Erratum in: Radiother Oncol. 2013 May;107(2):263. Abderrhamani, Rym [corrected to Abderrahmani, Rym].

PMID:
23321494
19.

Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33.

Kong L, Giang E, Nieusma T, Robbins JB, Deller MC, Stanfield RL, Wilson IA, Law M.

J Virol. 2012 Dec;86(23):13085-8. doi: 10.1128/JVI.01939-12. Epub 2012 Sep 12.

20.

Production of hepatitis B defective particles is dependent on liver status.

Redelsperger F, Lekbaby B, Mandouri Y, Giang E, Duriez M, Desire N, Roque Afonso AM, Brichler S, Dubreuil P, Dobrin A, Perlemuter G, Prevot S, Bacon N, Grange JD, Zatla F, Le Pendeven C, Pol S, Strick-Marchand H, Di Santo J, Kremsdorf D, Soussan P.

Virology. 2012 Sep 15-30;431(1-2):21-8. doi: 10.1016/j.virol.2012.05.008. Epub 2012 Jun 2.

21.

Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.

Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9499-504. doi: 10.1073/pnas.1202924109. Epub 2012 May 23.

22.

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.

Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6205-10. doi: 10.1073/pnas.1114927109. Epub 2012 Apr 4. Erratum in: Proc Natl Acad Sci U S A. 2017 Dec 11;:.

23.

Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice.

Brezillon N, Brunelle MN, Massinet H, Giang E, Lamant C, DaSilva L, Berissi S, Belghiti J, Hannoun L, Puerstinger G, Wimmer E, Neyts J, Hantz O, Soussan P, Morosan S, Kremsdorf D.

PLoS One. 2011;6(12):e25096. doi: 10.1371/journal.pone.0025096. Epub 2011 Dec 5.

24.

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.

Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR.

Nat Med. 2008 Jan;14(1):25-7. Epub 2007 Dec 6.

PMID:
18064037

Supplemental Content

Support Center